Kristofer James Thurecht - Nanotechnology

Author Information

Kristofer James Thurecht is affiliated with the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, St Lucia, Queensland 4072, Australia. His research is primarily focused on nanotechnology and its applications in medicine, particularly in the development and characterization of nanoparticle-based medicines and antibody engineering.

Research Contributions

Kristofer James Thurecht has made significant contributions to the field of nanotechnology, particularly in the context of biomedical applications. His recent work includes the development of template-assisted antibody assembly for engineering functional antibody nanoparticles, strategies for evading and manipulating the mononuclear phagocyte system in nanoparticle-based medicines, and understanding nanomedicine treatment in aggressive brain cancer models. He has also contributed to the clinical development of anti-GPC-1 antibodies for cancer treatment, and the synthesis and evaluation of hyperbranched polymers for drug delivery. His research has been pivotal in advancing the understanding of how nanomaterials interact biologically and how they can be harnessed for therapeutic purposes.

Aliases

Kristofer James Thurecht is also known by various aliases including Kristofer Thurecht, K. J. Thurecht, Kris Thurecht, Kristofer J. Thurecht, and K J Thurecht.

Publication and Citation Metrics

Metric	Value
Total Citation Count	7427
h-index	41
Total Paper Count	234

Publications:

Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles

DOI: 10.1021/acs.chemmater.1c04397

Year: 2022

Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation.

DOI: 10.1039/d2bm00181k

Year: 2022

Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.

DOI: 10.1016/j.biomaterials.2022.121416

Year: 2022

Clinical development of an anti-GPC-1 antibody for the treatment of cancer

DOI: 10.1080/14712598.2022.2033204

Year: 2022

Simultaneous Dual Echo Gadolinium Enhanced MR-PET for Evaluation of PET Tracer Delivery in Altered Pathophysiology

DOI: 10.3389/fphy.2022.759749

Year: 2022

Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery.

DOI: 10.1021/acs.molpharmaceut.1c00996

Year: 2022

Synthesis, characterisation and evaluation of hyperbranched N-(2-hydroxypropyl) methacrylamides for transport and delivery in pancreatic cell lines in vitro and in vivo.

DOI: 10.1039/d1bm01548f

Year: 2022

Celebrating Women in the Pharmaceutical Sciences.

DOI: 10.1021/acs.molpharmaceut.0c01197

Year: 2021

Poly(2-ethyl-2-oxazoline) bottlebrushes: How nanomaterial dimensions can influence biological interactions

DOI: 10.1016/J.EURPOLYMJ.2021.110447

Year: 2021

Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study

DOI: 10.1007/s10620-020-06752-y

Year: 2021

How do EUV Resists Work?

Why are Joint Ventures Important in Nanotechnology?

What Are Nanotechnology-Based Surveillance Devices?

How is Nanotechnology Disrupting Traditional Industries?

What is the significance of X-ray Diffraction (XRD) in Nanotechnology?

How Can One Get Involved with AIMBE in the Field of Nanotechnology?

What is Synchronization in Nanotechnology?

How Does Nanotechnology Enhance Pharmacokinetics?

How does SPL compare to other nanolithography techniques?

What is Plasmon Resonance?

Partnered Content Networks

Relevant Topics